Showing results 4 to 9 of 9
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects. Poster Presentation (SAT443) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology | 2022 | ||
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Clinical Oncology | 2012 | ||
Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma Journal:Clinical Cancer Research | 2018 | ||
2016 | |||
2016 | |||
The pharmacokinetic and safety profiles of RO7445482 SIRNA are similar between Asian and nonAsian healthy volunteers and chronic hepatitis B patients in a phase 1 Study Proceeding/Conference:Poster presentation at the AASLD The Liver Meeting, November 12-15. 2021. Hepatology | 2021 |